Abstract
Over the past decade, our laboratory has developed a secreted heat shock protein (HSP), chaperone gp96, cell-based vaccine that generates effective anti-tumor and anti-infectious immunity in vivo. Gp96-peptide complexes were identified as an extremely efficient stimulator of MHC I-mediated antigen cross-presentation, generating CD8 cytotoxic T-lymphocyte responses detectable in blood, spleen, gut and reproductive tract to femto-molar concentrations of antigen these studies provided the first evidence that cell-based gp96-Ig-secreting vaccines may serve as a potent modality to induce both systemic and mucosal immunity. This approach takes advantage of the combined adjuvant and antigen delivery capacity of gp96 for the generation of cytotoxic immunity against a wide range of antigens in both anti-vial and anti-cancer vaccination. Here, we review the vaccine design that utilizes the unique property/ability of endoplasmic HSP gp96 to bind antigenic peptides and deliver them to antigen-presenting cells. © 2013 Springer Science+Business Media New York.
Author supplied keywords
Cite
CITATION STYLE
Strbo, N., Garcia-Soto, A., Schreiber, T. H., & Podack, E. R. (2013). Secreted heat shock protein gp96-Ig: Next-generation vaccines for cancer and infectious diseases. Immunologic Research, 57(1–3), 311–325. https://doi.org/10.1007/s12026-013-8468-x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.